p.103 抽出テキスト

regurgitation: 5-year results from the EuroSMR registry. JACC Cardiovasc Interv 2024;17:2543–54. https://doi.org/10.1016/j.jcin.2024.08.016 770. Heitzinger G, Pavo N, Koschatko S, Jantsch C, Winter MP, Spinka G, et al. Contemporary insights into the epidemiology, impact and treatment of secondary tricuspid regurgitation across the heart failure spectrum. Eur J Heart Fail 2023;25:857–67. https://doi.org/10.1002/ejhf.2858 771. Metra M, Tomasoni D, Adamo M, Anker SD, Bayes-Genis A, von Bardeleben RS, et al. Evidence generation and implementation of transcatheter interventions for atrioventricular valvular heart disease in heart failure: current status and future directions. Circulation 2025;151:1342–63. https://doi.org/10. 1161/CIRCULATIONAHA.124.070411 772. Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P, et al. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med 2023;388:1833–42. https://doi.org/10.1056/NEJMoa2300525 773. Donal E, Dreyfus J, Leurent G, Coisne A, Leroux PY, Ganivet A, et al. Transcatheter edge-to-edge repair for severe isolated tricuspid regurgitation: the Tri.Fr randomized clinical trial. JAMA 2025;333:124–32. https:// doi.org/10.1001/jama.2024.21189 774. Hahn RT, Makkar R, Thourani VH, Makar M, Sharma RP, Haeffele C, et al. Transcatheter valve replacement in severe tricuspid regurgitation. N Engl J Med 2025;392:115–26. https://doi.org/10.1056/NEJMoa2401918 775. Kar S, Makkar RR, Whisenant BK, Hamid N, Naik H, Tadros P, et al. Two-year outcomes of transcatheter edge-to-edge repair for severe tricuspid regurgitation: the TRILUMINATE pivotal randomized controlled trial. Circulation 2025; 151:1630–8. https://doi.org/10.1161/CIRCULATIONAHA.125.074536 776. Tomasoni D, Adamo M, Hausleiter J, Pezzola E, Kresoja KP, von Stein J, et al. Heart failure hospitalizations and clinical outcomes in patients undergoing tricuspid transcatheter edge-to-edge repair: insights from EuroTR. Eur J Heart Fail 2025;27:1559–69. https://doi.org/10.1002/ejhf.3757 777. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 2014;383:1899–911. https://doi.org/10.1016/S0140- 6736(14)60685-1 778. Tomasoni D, Vitale C, Guidetti F, Benson L, Braunschweig F, Dahlstrom U, et al. The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: data from the Swedish Heart Failure Registry. Eur J Heart Fail 2024;26:854–68. https://doi.org/10. 1002/ejhf.3112 779. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003;5:659–67. https://doi.org/10.1016/s1388- 9842(03)00163-6 780. Cautela J, Tartiere JM, Cohen-Solal A, Bellemain-Appaix A, Theron A, Tibi T, et al. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. Eur J Heart Fail 2020;22:1357–65. https:// doi.org/10.1002/ejhf.1835 781. Vemmos K, Ntaios G, Savvari P, Vemmou AM, Koroboki E, Manios E, et al. Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke: a 10-year follow-up study. Eur J Heart Fail 2012;14: 211–8. https://doi.org/10.1093/eurjhf/hfr172 782. Divani AA, Vazquez G, Asadollahi M, Qureshi AI, Pullicino P. Nationwide frequency and association of heart failure on stroke outcomes in the United States. J Card Fail 2009;15:11–6. https://doi.org/10.1016/j.cardfail.2008. 09.001 783. Ois A, Gomis M, Cuadrado-Godia E, Jimenez-Conde J, Rodriguez-Campello A, Bruguera J, et al. Heart failure in acute ischemic stroke. J Neurol 2008; 255:385–9. https://doi.org/10.1007/s00415-008-0677-1 784. Hays AG, Sacco RL, Rundek T, Sciacca RR, Jin Z, Liu R, et al. Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population. Stroke 2006;37:1715–9. https://doi.org/10.1161/01.STR.0000227121. 34717.40 785. Witt BJ, Gami AS, Ballman KV, Brown RD Jr, Meverden RA, Jacobsen SJ, et al. The incidence of ischemic stroke in chronic heart failure: a meta-analysis. J Card Fail 2007;13:489–96. https://doi.org/10.1016/j.cardfail.2007.01.009 786. Witt BJ, Brown RD Jr, Jacobsen SJ, Weston SA, Ballman KV, Meverden RA, et al. Ischemic stroke after heart failure: a community-based study. Am Heart J 2006;152:102–9. https://doi.org/10.1016/j.ahj.2005.10.018 787. Lip GY, Rasmussen LH, Skjoth F, Overvad K, Larsen TB. Stroke and mortality in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. BMJ Open 2012;2:e000975. https://doi.org/10.1136/bmjopen- 2012-000975 788. Alberts VP, Bos MJ, Koudstaal P, Hofman A, Witteman JC, Stricker B, et al. Heart failure and the risk of stroke: the Rotterdam Study. Eur J Epidemiol 2010;25:807–12. https://doi.org/10.1007/s10654-010-9520-y 789. Adelborg K, Szepligeti S, Sundboll J, Horvath-Puho E, Henderson VW, Ording A, et al. Risk of stroke in patients with heart failure: a population-based 30-year cohort study. Stroke 2017;48:1161–8. https://doi.org/10.1161/ STROKEAHA.116.016022 790. Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005;112:3738–44. https://doi. org/10.1161/CIRCULATIONAHA.105.561423 791. Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 2010;121:1393–405. https://doi.org/10.1161/ CIRCULATIONAHA.109.909614 792. Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol 2016; 203:660–6. https://doi.org/10.1016/j.ijcard.2015.10.220 793. McManus DD, Hsu G, Sung SH, Saczynski JS, Smith DH, Magid DJ, et al. Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction. J Am Heart Assoc 2013;2:e005694. https://doi. org/10.1161/JAHA.112.005694 794. Sandhu RK, Hohnloser SH, Pfeffer MA, Yuan F, Hart RG, Yusuf S, et al. Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. Stroke 2015;46:667–72. https://doi.org/10.1161/STROKEAHA. 114.007140 795. Uhm JS, Kim J, Yu HT, Kim TH, Lee SR, Cha MJ, et al. Stroke and systemic embolism in patients with atrial fibrillation and heart failure according to heart failure type. ESC Heart Fail 2021;8:1582–9. https://doi.org/10.1002/ehf2. 13264 796. Chung S, Kim TH, Uhm JS, Cha MJ, Lee JM, Park J, et al. Stroke and systemic embolism and other adverse outcomes of heart failure with preserved and reduced ejection fraction in patients with atrial fibrillation (from the COmparison study of drugs for symptom control and complication prevention of atrial fibrillation [CODE-AF]). Am J Cardiol 2020;125:68–75. https:// doi.org/10.1016/j.amjcard.2019.09.035 797. Sharma JC, Fletcher S, Vassallo M, Ross I. Cardiovascular disease and outcome of acute stroke: influence of pre-existing cardiac failure. Eur J Heart Fail 2000;2:145–50. https://doi.org/10.1016/s1388-9842(00)00067-2 798. Abdul-Rahim AH, Fulton RL, Frank B, McMurray JJ, Lees KR, collaborators V. Associations of chronic heart failure with outcome in acute ischaemic stroke patients who received systemic thrombolysis: analysis from VISTA. Eur J Neurol 2015;22:163–9. https://doi.org/10.1111/ene.12548 799. Ling LH, Kistler PM, Kalman JM, Schilling RJ, Hunter RJ. Comorbidity of atrial fibrillation and heart failure. Nat Rev Cardiol 2016;13:131–47. https://doi. org/10.1038/nrcardio.2015.191 800. Kang SH, Kim J, Park JJ, Oh IY, Yoon CH, Kim HJ, et al. Risk of stroke in congestive heart failure with and without atrial fibrillation. Int J Cardiol 2017;248: 182–7. https://doi.org/10.1016/j.ijcard.2017.07.056 801. Ishiguchi H, Chen Y, Huang B, Gue Y, Correa E, Homma S, et al. Machine learning for stroke in heart failure with reduced ejection fraction but without atrial fibrillation: a post-hoc analysis of the WARCEF trial. Eur J Clin Invest 2025;55:e14360. https://doi.org/10.1111/eci.14360 802. Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GY. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA 2015;314:1030–8. https://doi.org/10.1001/jama. 2015.10725 803. Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012;366:1859–69. https://doi.org/10.1056/NEJMoa1202299 804. Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med 2018;379:1332–42. https://doi.org/10.1056/ NEJMoa1808848 805. Shantsila E, Koziel M, Lip GY. Anticoagulation versus placebo for heart failure in sinus rhythm. Cochrane Database Syst Rev 2021;5:CD003336. https://doi. org/10.1002/14651858.CD003336.pub4 806. Shantsila E, Lip GY. Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm. Cochrane Database Syst Rev 2016;9: CD003333. https://doi.org/10.1002/14651858.CD003333.pub3 807. Sandset EC, Anderson CS, Bath PM, Christensen H, Fischer U, Gasecki D, et al. European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. Eur Stroke J 2021;6:II. https://doi.org/10.1177/23969873211012133 Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026